{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:20:20Z","timestamp":1780449620993,"version":"3.54.1"},"reference-count":69,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Vaccines and therapeutics targeting viral surface glycoproteins are a major component of disease prevention for respiratory viral diseases. Over the years, vaccines have proven to be the most successful intervention for preventing disease. Technological advances in vaccine platforms that focus on viral surface glycoproteins have provided solutions for current and emerging pathogens like SARS-CoV-2, and our understanding of the structural basis for antibody neutralization is guiding the selection of other vaccine targets for respiratory viruses like RSV. This review discusses the role of viral surface glycoproteins in disease intervention approaches.<\/jats:p>","DOI":"10.3390\/v13040625","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T10:34:12Z","timestamp":1617705252000},"page":"625","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2924-9956","authenticated-orcid":false,"given":"Ralph A.","family":"Tripp","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Stambas","sequence":"additional","affiliation":[{"name":"School of Medicine, Geelong Waurn Ponds, Deakin University, Melbourne, VIC 3125, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/S2214-109X(19)30545-5","article-title":"Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: A systematic review and modelling study","volume":"8","author":"Wang","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S563","DOI":"10.1093\/infdis\/jiy662","article-title":"The etiological role of common respiratory viruses in acute respiratory infections in older adults: A systematic review and meta-analysis","volume":"222","author":"Shi","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/bmb\/61.1.215","article-title":"Acute upper airway infections","volume":"61","author":"West","year":"2002","journal-title":"Br. Med. Bull."},{"key":"ref_4","first-page":"1","article-title":"Current state of respiratory syncytial virus disease and management","volume":"3","author":"Chatterjee","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1017\/S0950268820000400","article-title":"The burden of respiratory syncytial virus in adults: A systematic review and meta-analysis","volume":"148","author":"Yerramalla","year":"2020","journal-title":"Epidemiol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1056\/NEJM197903083001004","article-title":"Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children","volume":"300","author":"Henderson","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM196207122670204","article-title":"Natural reinfection of adults by respiratory syncytial virus. Possible relation to mild upper respiratory disease","volume":"267","author":"Johnson","year":"1962","journal-title":"N. Engl. J. Med."},{"key":"ref_8","first-page":"38","article-title":"Influenza: Pathogenesis and host defense","volume":"7","author":"Bender","year":"1992","journal-title":"Semin. Respir. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1749-6632.1983.tb26881.x","article-title":"Aging and the mucosal-associated lymphoid system","volume":"409","author":"Szewczuk","year":"1983","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1007\/s00018-020-03557-0","article-title":"Revisiting respiratory syncytial virus\u2019s interaction with host immunity, towards novel therapeutics","volume":"77","author":"Efstathiou","year":"2020","journal-title":"Cell Mol. Life Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/thoraxjnl-2018-212212","article-title":"Respiratory syncytial virus (rsv): A scourge from infancy to old age","volume":"74","author":"Coultas","year":"2019","journal-title":"Thorax"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1128\/CMR.00010-16","article-title":"Respiratory syncytial virus: Infection, detection, and new options for prevention and treatment","volume":"30","author":"Griffiths","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.anai.2020.03.017","article-title":"The journey to a respiratory syncytial virus vaccine","volume":"125","author":"Mejias","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3389\/fimmu.2019.01675","article-title":"Biology of infection and disease pathogenesis to guide rsv vaccine development","volume":"10","author":"Chirkova","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.virusres.2011.09.020","article-title":"Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years","volume":"162","author":"Collins","year":"2011","journal-title":"Virus Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11262-006-0064-x","article-title":"Respiratory syncytial virus (rsv) evades the human adaptive immune system by skewing the th1\/th2 cytokine balance toward increased levels of th2 cytokines and ige, markers of allergy\u2014A review","volume":"33","author":"Becker","year":"2006","journal-title":"Virus Genes"},{"key":"ref_17","first-page":"2515135520981516","article-title":"Strategies for active and passive pediatric rsv immunization","volume":"9","author":"Eichinger","year":"2021","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/14712598.2020.1753696","article-title":"Up-to-date role of biologics in the management of respiratory syncytial virus","volume":"20","author":"Tripp","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lukacs, N.W., and Malinczak, C.A. (2020). Harnessing cellular immunity for vaccination against respiratory viruses. Vaccines (Basel), 8.","DOI":"10.3390\/vaccines8040783"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1089\/vim.2004.17.370","article-title":"Respiratory syncytial virus-induced immunoprotection and immunopathology","volume":"17","author":"Durbin","year":"2004","journal-title":"Viral Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1080\/21645515.2018.1472183","article-title":"A multifaceted approach to rsv vaccination","volume":"14","author":"Blanco","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coi.2015.04.005","article-title":"Novel antigens for rsv vaccines","volume":"35","author":"Graham","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1099\/0022-1317-68-8-2169","article-title":"Immunological differences between the envelope glycoproteins of two strains of human respiratory syncytial virus","volume":"68","author":"Walsh","year":"1987","journal-title":"J. Gen. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Phung, E., Chang, L.A., Morabito, K.M., Kanekiyo, M., Chen, M., Nair, D., Kumar, A., Chen, G.L., Ledgerwood, J.E., and Graham, B.S. (2019). Epitope-specific serological assays for rsv: Conformation matters. Vaccines (Basel), 7.","DOI":"10.3390\/vaccines7010023"},{"key":"ref_25","first-page":"1062","article-title":"Broad antibody and cellular immune response from a phase 2 clinical trial with a novel multivalent poxvirus based rsv vaccine","volume":"29","author":"Jordan","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2018.10.001","article-title":"Nasal immunization with rsv f and g protein fragments conjugated to an m cell-targeting ligand induces an enhanced immune response and protection against rsv infection","volume":"159","author":"Khan","year":"2018","journal-title":"Antiviral Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1750-2659.2011.00304.x","article-title":"Influenza neuraminidase","volume":"6","author":"Air","year":"2012","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.chom.2015.02.012","article-title":"Influenza vaccines: Challenges and solutions","volume":"17","author":"Houser","year":"2015","journal-title":"Cell Host Microbe"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1586\/14760584.2014.922417","article-title":"Development of live attenuated influenza vaccines against pandemic influenza strains","volume":"13","author":"Coelingh","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12985-017-0918-y","article-title":"Towards a universal influenza vaccine: Different approaches for one goal","volume":"15","author":"Sautto","year":"2018","journal-title":"Virol. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1056\/NEJMp2027405","article-title":"Developing safe and effective covid vaccines - operation warp speed\u2019s strategy and approach","volume":"383","author":"Slaoui","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jama.2020.12190","article-title":"Developing a sars-cov-2 vaccine at warp speed","volume":"324","author":"Blatz","year":"2020","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41592-020-0827-7","article-title":"Coronavirus jolts labs to warp speed","volume":"17","author":"Marx","year":"2020","journal-title":"Nat. Methods"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.xphs.2020.11.010","article-title":"Warp-speed covid-19 vaccine development: Beneficiaries of maturation in biopharmaceutical technologies and public-private partnerships","volume":"110","author":"Ho","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e01083","DOI":"10.1128\/JVI.01083-20","article-title":"Covid-19 vaccines: \u201cWarp speed\u201d needs mind melds, not warped minds","volume":"94","author":"Moore","year":"2020","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Noor, R. (2021). Developmental status of the potential vaccines for the mitigation of the covid-19 pandemic and a focus on the effectiveness of the pfizer-biontech and moderna mrna vaccines. Curr. Clin. Microbiol. Rep., 1\u20138.","DOI":"10.1007\/s40588-021-00162-y"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Bettini, E., and Locci, M. (2021). Sars-cov-2 mrna vaccines: Immunological mechanism and beyond. Vaccines (Basel), 9.","DOI":"10.3390\/vaccines9020147"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-030-59261-5_5","article-title":"Relationship between covid-19 and angiotensin-converting enzyme 2: A scoping review","volume":"1321","author":"Shojaee","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijbiomac.2021.01.076","article-title":"Trends and strategies to combat viral infections: A review on fda approved antiviral drugs","volume":"172","author":"Tompa","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Leroy, H., Han, M., Woottum, M., Bracq, L., Bouchet, J., Xie, M., and Benichou, S. (2020). Virus-mediated cell-cell fusion. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249644"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1080\/1061186X.2020.1792916","article-title":"Envelope proteins as antiviral drug target","volume":"28","author":"Verma","year":"2020","journal-title":"J. Drug Target"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40121-020-00383-6","article-title":"The future of respiratory syncytial virus disease prevention and treatment","volume":"10","author":"Domachowske","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s13238-010-0054-6","article-title":"Roles of the hemagglutinin of influenza a virus in viral entry and development of antiviral therapeutics and vaccines","volume":"1","author":"Jiang","year":"2010","journal-title":"Protein Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0042-6822(74)90276-1","article-title":"Characterization of temperature sensitive influenza virus mutants defective in neuraminidase","volume":"61","author":"Palese","year":"1974","journal-title":"Virology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/ja963036t","article-title":"Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity","volume":"119","author":"Kim","year":"1997","journal-title":"J. Am. Chem. Soc."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/363418a0","article-title":"Rational design of potent sialidase-based inhibitors of influenza virus replication","volume":"363","author":"Wu","year":"1993","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0969-2126(93)90005-2","article-title":"Influenza b virus neuraminidase can synthesize its own inhibitor","volume":"1","author":"Burmeister","year":"1993","journal-title":"Structure"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199936001-00001","article-title":"Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers","volume":"36","author":"Cass","year":"1999","journal-title":"Clin. Pharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1021\/jm0002679","article-title":"Bcx-1812 (rwj-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design","volume":"43","author":"Babu","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/135965350501000805","article-title":"Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: Randomized, controlled trials for prophylaxis and treatment","volume":"10","author":"Barroso","year":"2005","journal-title":"Antivir. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1126\/science.144.3620.862","article-title":"Antiviral activity of 1-adamantanamine (amantadine)","volume":"144","author":"Davies","year":"1964","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"a038505","DOI":"10.1101\/cshperspect.a038505","article-title":"The structure, function, and pathobiology of the influenza a and b virus ion channels","volume":"10","author":"Lamb","year":"2020","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.resinv.2018.10.002","article-title":"Baloxavir heralds a new era in influenza virus biology","volume":"57","author":"Kikuchi","year":"2019","journal-title":"Respir. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/cid\/ciy874","article-title":"Clinical practice guidelines by the infectious diseases society of america: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Dong, G., Peng, C., Luo, J., Wang, C., Han, L., Wu, B., Ji, G., and He, H. (2015). Adamantane-resistant influenza a viruses in the world (1902\u20132013): Frequency and distribution of m2 gene mutations. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119115"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.07.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016\u20132017","volume":"157","author":"Lackenby","year":"2018","journal-title":"Antiviral Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0166-3542(01)00124-3","article-title":"Position statement: Global neuraminidase inhibitor susceptibility network","volume":"49","author":"Zambon","year":"2001","journal-title":"Antiviral Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Checkmahomed, L., Padey, B., Pizzorno, A., Terrier, O., Rosa-Calatrava, M., Abed, Y., Baz, M., and Boivin, G. (2020). In Vitro combinations of baloxavir acid and other inhibitors against seasonal influenza a viruses. Viruses, 12.","DOI":"10.3390\/v12101139"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"104545","DOI":"10.1016\/j.antiviral.2019.104545","article-title":"Antivirals targeting the polymerase complex of influenza viruses","volume":"169","author":"Mifsud","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11010-020-03924-2","article-title":"Role of ace2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in covid-19","volume":"476","author":"Kumar","year":"2021","journal-title":"Mol. Cell Biochem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"111232","DOI":"10.1016\/j.biopha.2021.111232","article-title":"Human endeavor for anti-sars-cov-2 pharmacotherapy: A major strategy to fight the pandemic","volume":"137","author":"Wang","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Elshabrawy, H.A. (2020). Sars-cov-2: An update on potential antivirals in light of sars-cov antiviral drug discoveries. Vaccines (Basel), 8.","DOI":"10.3390\/vaccines8020335"},{"key":"ref_64","first-page":"31","article-title":"Convalescent plasma for the treatment of severe covid-19","volume":"15","author":"Franchini","year":"2021","journal-title":"Biologics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1080\/21645515.2020.1787074","article-title":"Neutralizing and cross-reacting antibodies: Implications for immunotherapy and sars-cov-2 vaccine development","volume":"17","author":"Cohen","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.chom.2020.11.008","article-title":"Freting over sars-cov-2: Conformational dynamics of the spike glycoprotein","volume":"28","author":"Serrao","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acsinfecdis.0c00168","article-title":"Characterization and noncovalent inhibition of the deubiquitinase and deisgylase activity of sars-cov-2 papain-like protease","volume":"6","author":"Freitas","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"636738","DOI":"10.3389\/fmolb.2020.636738","article-title":"Therapeutic strategies in the management of covid-19","volume":"7","author":"Naik","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Gavriatopoulou, M., Ntanasis-Stathopoulos, I., Korompoki, E., Fotiou, D., Migkou, M., Tzanninis, I.G., Psaltopoulou, T., Kastritis, E., Terpos, E., and Dimopoulos, M.A. (2020). Emerging treatment strategies for covid-19 infection. Clin. Exp. Med., 1\u201313.","DOI":"10.1007\/s10238-020-00671-y"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/4\/625\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:58:40Z","timestamp":1760363920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/4\/625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":69,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["v13040625"],"URL":"https:\/\/doi.org\/10.3390\/v13040625","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,6]]}}}